MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special storage requirements.

Provenance

This compatibility recommendation is derived from Imigran Radis 50mg tablets (GlaxoSmithKline UK Ltd), Imigran 50mg tablets (GlaxoSmithKline UK Ltd) and generic sumatriptan 50mg tablets.

Stability Notes

Should be stored in tight, light resistant containers and protected from excessive moisture.

Provenance

This compatibility recommendation is derived from Clarityn Allergy 10mg tablets (Bayer Plc) and Loratadine 10mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light and store in airtight containers.

Provenance

Compatibility recommendation derived from Paracetamol 500mg capsules (Zentiva Pharma UK Ltd).

Stability Notes

Use airtight and light resistant container.

Provenance

Compatibility information derived from Naprosyn EC 250mg tablets (Atnahs Pharma UK Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Fluconazole 150mg capsules (Accord Healthcare Ltd), Fluconazole 150mg capsules (Kent Pharma (UK) Ltd) and Diflucan 150mg capsules (Pfizer Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.